A small, senior-led practice for founders, executives, and their investors. Founded by Patrick van Berkel after three decades in industry.
Engagements are senior-led and deliberately scoped.
Independent technical reviews of assets, platforms, and pipelines for venture, corporate development, and licensing decisions.
Targets, biomarker plans, model selection, and the leap from in vivo data to first-in-human.
Process development, analytical strategy, and CMC planning aligned to clinical and capital timelines.
Portfolio reviews built on probability of success, market reality, and capital efficiency.
Decks, data rooms, and narrative support for fundraises, partnerships, and out-licensing.
Four moves, in order.
The question behind the question. The hardest decisions are rarely the ones you arrived asking about.
Primary literature, internal datasets, regulatory precedent, and adjacent programs — read carefully, stress-tested.
Recommendations arrive with the trade-offs visible. You should be able to interrogate the logic, not take our word.
The deliverable is rarely the end of the work. We stay close through execution when it matters.
Deep, not broad. Depth in a small number of areas beats surface knowledge across many.
Betulamab is a one-person practice by design. Every engagement is led by the founder.
Protein engineering — Betulamab's home ground.
Three decades in biotech across start-ups and mid-sized companies. Actively involved in advancing multiple programs from bench to clinic and market — the full arc, not just a phase.
Betulamab exists because good biotech decisions require both scientific depth and a working understanding of how programs actually move. The two are rarer in combination than they should be.
Clients are early-stage biotechs, growth-stage companies at major inflection points, and the investors who back them. Engagements are small in number, senior in delivery.
A few sentences on the program, decision, or question is usually enough to start. Replies within two business days.
Direct is fine, and often faster:
info@betulamab.nl